Pegylated Liposomal Doxorubicin (Caelyx®) in Metastatic Breast Cancer: A Community-Based Observation Study

Abstract

This community-based observational study supports previous reports indicating that PLD at a median dose of < or =40 mg/m(2) every 4 weeks is an active, well-tolerated agent in non-selected, pretreated patients with metastatic breast cancer.